Watching ACADIA Pharmaceuticals; Traders Circulate "ACADIA Pharmaceuticals Wins Summary Judgement In A Patent Suit Regarding Its Drug Nuplazid, Which Is Used To Treat Parkinson's Disease, Against Generic Maker MSN Laboratories"; Shares Now Up 27%
Portfolio Pulse from Benzinga Newsdesk
Acadia Pharmaceuticals (NASDAQ:ACAD) experienced a 32% surge in stock price after winning a summary judgment in a patent lawsuit over its Parkinson's disease drug, Nuplazid, against generic drug manufacturer MSN Laboratories. The U.S. District Court Judge Gregory B. Williams ruled in favor of Acadia, which had filed lawsuits last October claiming that copies of Nuplazid infringed on a patent.
December 13, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acadia Pharmaceuticals' stock price jumped significantly due to a favorable court ruling in a patent infringement case concerning its drug Nuplazid.
The positive outcome of the patent lawsuit is a significant win for Acadia Pharmaceuticals, as it protects their drug Nuplazid from generic competition. This legal victory is likely to boost investor confidence and support the stock price in the short term, as it secures the company's revenue stream from this particular drug.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100